The human immune system operates like a finely tuned orchestra, where every instrument must join in and fall silent at precisely the right moment. When a critical "off-switch" known as CTLA-4 fails due to a genetic defect, this harmony dissolves into chaos. Immune cells begin attacking the body's own tissues, leading to chronic inflammation, bowel disease, blood disorders, and a heightened vulnerability to infections.
CTLA-4 deficiency is a rare hereditary condition that typically manifests during childhood. Until now, treatment has primarily focused on dampening the immune system's overactivity through immunosuppressant drugs or, in the most severe cases, high-risk bone marrow transplants.
Researchers at University College London, in collaboration with the charity LifeArc, NHS Blood and Transplant, and Great Ormond Street Hospital, have proposed a novel approach. They are developing a therapy where a patient's own T-cells are extracted, corrected for the genetic defect using CRISPR/Cas9 gene-editing technology, and then returned to the body.
Preclinical studies have demonstrated that once edited, these cells regain the ability to produce functional CTLA-4 protein and more effectively restrain immune overactivation in laboratory settings. The project is now advancing to its next phase: preparing the viral vector and manufacturing the cell product for Phase 1 clinical trials.
Pending regulatory approval, the Phase 1 study is scheduled to begin in 2028. It is expected to enroll up to eight patients ranging in age from one to 65 years.
NHS Blood and Transplant will handle the production of the viral vector, while Great Ormond Street Hospital will be responsible for manufacturing the cell therapy product. Clinical trials will also take place at University College London and the Royal Free Hospital in London. This partnership between universities, public health services, and charitable organizations highlights the growing importance of developing personalized genetic treatments for rare diseases.
According to lead researcher Dr. Thomas Fox, correcting the genetic defect directly within the patient’s own T-cells makes it possible to target the root cause of the disease rather than merely managing its symptoms. Professor Claire Booth emphasizes that the project’s primary goal is to translate breakthroughs in basic science into real-world treatments for children and adults with severe hereditary immune disorders.
Patient advocacy groups for primary immunodeficiencies have also hailed the project as a major step forward. For many families living with this rare condition, it offers the prospect of an entirely new treatment option.
If clinical trials confirm the safety and efficacy of the method, this approach could serve as a template for treating other rare hereditary immunodeficiencies. This reflects a broader shift in modern genomic medicine: moving away from lifelong symptom management toward curing the underlying cause using a patient’s own cells.
This project represents a significant breakthrough in the treatment of rare genetic immunodeficiencies. The successful implementation of genome-editing therapy to correct CTLA-4 deficiency could radically transform patient outcomes, replacing arduous and often inconsistent treatments with targeted, personalized therapy.
This marks a vital step toward the medicine of the future.
